Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Nature Reviews. Cancer

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrc2545PMID 19104515
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Retargeting polymer‐coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer

  2008cited by this paper
• Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

  2008cited by this paper
• Chemical control of protein stability and function in living mice

  2008cited by this paper
• Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene

  2008cited by this paper
• Vaccinia Virus Uses Macropinocytosis and Apoptotic Mimicry to Enter Host Cells

  2008cited by this paper
• Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.

  2008cited by this paper
• Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus

  2008cited by this paper
• Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy

  2008cited by this paper
• Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

  2008cited by this paper
• Reovirus: viral therapy for cancer 'as nature intended'.

  2008cited by this paper
• Vaccinia Virus Uses Macropinocytosis and Apoptotic Mimicry to Enter Host Cells

  2008cited by this paper
• Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop.

  2008cited by this paper
• The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.

  2008cited by this paper
• Vaccination of Prostate Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax): A Phase 2 Trial

  2008cited by this paper
• New developments in multitargeted therapy for patients with solid tumours.

  2008cited by this paper
• Virus combinations and chemotherapy for the treatment of human cancers.

  2008cited by this paper
• From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.

  2008cited by this paper
• Enhancing poxvirus oncolytic effects through increased spread and immune evasion.

  2008cited by this paper
• Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.

  2007cited by this paper
• Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

  2007cited by this paper
• Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.

  2007cited by this paper
• A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus

  2007cited by this paper
• Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine.

  2007cited by this paper
• Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

  2007cited by this paper
• Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox.

  2007cited by this paper
• Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta.

  2007cited by this paper
• Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies

  2007cited by this paper
• Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow.

  2007cited by this paper
• Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia Virus

  2007cited by this paper
• Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.

  2007cited by this paper
• The Vaccinia Virus Protein F1L Interacts with Bim and Inhibits Activation of the Pro-apoptotic Protein Bax*

  2006cited by this paper
• Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

  2006cited by this paper
• Stem cells and cancer: two faces of eve.

  2006cited by this paper
• Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy.

  2006cited by this paper
• The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

  2006cited by this paper
• Protective Immunity against Secondary Poxvirus Infection Is Dependent on Antibody but Not on CD4 or CD8 T-Cell Function

  2006cited by this paper
• Stem cells: the real culprits in cancer?

  2006cited by this paper
• Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy.

  2006cited by this paper
• Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor.

  2006cited by this paper
• Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

  2006cited by this paper
• Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients

  2006cited by this paper
• Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

  2006cited by this paper
• Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.

  2006cited by this paper
• Randomised controlled trial

  2006cited by this paper
• Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination

  2006cited by this paper
• A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor

  2006cited by this paper
• Synergistic Antitumor Effects of Immune Cell-Viral Biotherapy

  2006cited by this paper
• CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor–Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer

  2006cited by this paper
• Poxvirus entry and membrane fusion.

  2006cited by this paper
• Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases

  2005cited by this paper
• Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells

  2005cited by this paper
• Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.

  2005cited by this paper
• The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.

  2005cited by this paper
• Recent progress in the battle between oncolytic viruses and tumours

  2005cited by this paper
• An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge

  2005cited by this paper
• Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects.

  2005cited by this paper
• High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

  2005cited by this paper
• Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread.

  2005cited by this paper
• Spying on cancer: molecular imaging in vivo with genetically encoded reporters.

  2005cited by this paper
• Using in Vivo Bioluminescence Imaging to Shed Light on Cancer Biology

  2005cited by this paper
• Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction.

  2005cited by this paper
• Pox viral vaccine approaches.

  2005cited by this paper
• Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier

  2004cited by this paper
• Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins

  2004cited by this paper
• Vaccinia Virus Intermediate Stage Transcription Is Complemented by Ras-GTPase-activating Protein SH3 Domain-binding Protein (G3BP) and Cytoplasmic Activation/Proliferation-associated Protein (p137) Individually or as a Heterodimer*

  2004cited by this paper
• Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide.

  2004cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Poxvirus vaccines for cancer and HIV therapy

  2004cited by this paper
• Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.

  2004cited by this paper
• The two faces of Eve

  2004cited by this paper
• Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery.

  2003cited by this paper
• Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel.

  2003cited by this paper
• Clinical development of gene therapy for colorectal cancer

  2003cited by this paper
• Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer

  2003cited by this paper
• Smallpox vaccination and adverse reactions. Guidance for clinicians.

  2003cited by this paper
• VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

  2003cited by this paper
• Mutations in the Vaccinia Virus A33R and B5R Envelope Proteins That Enhance Release of Extracellular Virions and Eliminate Formation of Actin-Containing Microvilli without Preventing Tyrosine Phosphorylation of the A36R Protein

  2003cited by this paper
• Why did p53 gene therapy fail in ovarian cancer?

  2003cited by this paper
• Poxviruses as vectors for cancer immunotherapy.

  2003cited by this paper
• Getting oncolytic virus therapies off the ground.

  2003cited by this paper
• In Search of a Kinder, Gentler Vaccine

  2002cited by this paper
• Bioterrorism. In search of a kinder, gentler vaccine.

  2002cited by this paper
• Adenovirus Biodistribution and Noninvasive Imaging of Gene Expression In Vivo by Positron Emission Tomography Using Human Sodium/Iodide Symporter as Reporter Gene

  2002cited by this paper
• Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.

  2002cited by this paper
• Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.

  2002cited by this paper
• Cancer immunotherapy with natural killer cells.

  2002cited by this paper
• Cidofovir in the treatment of poxvirus infections

  2002cited by this paper
• Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.

  2001cited by this paper
• Faculty Opinions recommendation of A mitogenic signal triggered at an early stage of vaccinia virus infection: implication of MEK/ERK and protein kinase A in virus multiplication.

  2001cited by this paper
• A Mitogenic Signal Triggered at an Early Stage of Vaccinia Virus Infection

  2001cited by this paper
• Cancer gene therapy: fringe or cutting edge?

  2001cited by this paper
• Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.

  2001cited by this paper
• Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

  2001cited by this paper
• Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production.

  2001cited by this paper
• Clinical evaluation of a vaccinia‐vectored Hantaan virus vaccine

  2000cited by this paper
• Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.

  2000cited by this paper
• An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

  2000cited by this paper
• Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

  2000cited by this paper
• Reovirus as a novel oncolytic agent.

  2000cited by this paper
• In vivo magnetic resonance imaging of transgene expression

  2000cited by this paper

• Immune-Centered Cross-Talk Between Cancer Cells and the Tumor Microenvironment—Implications for Therapy

  2026cites this paper
• Advances of oncolytic vaccinia viruses armed with interleukin in tumor therapy

  2025cites this paper
• Advances in the use of nanoparticles for specific cell-target delivery of anti-cancer agents.

  2025cites this paper
• Oncolytic virus and immunogenic cell death in cancer therapy

  2025cites this paper
• Oncolytic viral therapy as a novel potential solution for treatment of pancreatic cancer

  2025cites this paper
• Replication-competent vaccinia virus-vectored oral vaccines provide complete protection against the SARS-CoV-2 challenge and effectively prevent viral transmission via respiratory droplets in mice and minks

  2025cites this paper
• Current and emerging concepts for systemic treatment of metastatic colorectal cancer

  2025cites this paper
• Development of attenuated Orf virus as a safe oncolytic viral vector for nasopharyngeal carcinoma treatment

  2025cites this paper
• Oncolytic Virotherapy in Solid Tumors: A Current Review

  2025cites this paper
• Targeted Inhibition of p21 Promotes the Growth of Breast Cancer Cells and Impairs the Tumor-Killing Effect of the Vaccinia Virus

  2024cites this paper
• Oncolytic vaccinia virus and cancer immunotherapy

  2024cites this paper
• Filamin B restricts vaccinia virus spread and is targeted by vaccinia virus protein C4

  2024cites this paper
• Strategies for engineering oncolytic viruses to enhance cancer immunotherapy

  2024cites this paper
• Nanoengineering‐armed oncolytic viruses drive antitumor response: progress and challenges

  2024cites this paper
• Viral/Non-Viral Vectors in DNA/RNA Delivery Technology

  2024cites this paper
• A Recombinant Vaccinia Virus Expressing a Sodium/Iodide Symporter for Theranostics of Malignant Tumors Using Synchrotron Radiation

  2024cites this paper
• Recent progress in combination therapy of oncolytic vaccinia virus

  2024cites this paper
• Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12

  2024cites this paper
• HDAC5 enhances IRF3 activation and is targeted for degradation by protein C6 from orthopoxviruses including Monkeypox virus and Variola virus

  2024cites this paper
• Interferon type I-expressing recombinant vaccinia virus as a platform for selective immunotherapy of glioblastoma and melanoma

  2024cites this paper
• A new MVA ancestor-derived oncolytic vaccinia virus induces immunogenic tumor cell death and robust antitumor immune responses

  2024cites this paper
• Application of Oncolytic Poxviruses: An Emerging Paradigm in Cancer Therapy.

  2024cites this paper
• Enhanced Antitumor Efficacy of Oncolytic Vaccinia Virus Therapy Through Keratin-Mediated Delivery in Triple-Negative Breast Cancer

  2024cites this paper
• Genetically Engineered Microorganisms and Their Impact on Human Health

  2024cites this paper
• CURRENT PERSPECTIVES OF VIROTHERAPY AS A CANCER TREATMENT STRATEGY

  2024cites this paper
• Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review

  2023cites this paper
• Application of oncolytic virus in tumor therapy

  2023cites this paper
• Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy

  2023cites this paper
• Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer

  2023cites this paper
• Oncolytic virotherapies for pediatric tumors

  2023cites this paper
• Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy

  2023cites this paper
• Global trends of Vaccinia oncolytic virus therapy over the past two decades: Bibliometric and visual analysis

  2023cites this paper
• Tumor Tropism of DNA Viruses for Oncolytic Virotherapy

  2023cites this paper
• Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity

  2023cites this paper
• Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages

  2023cites this paper
• Oncolytic myxoma virus is effective in murine models of triple negative breast cancer despite poor rates of infection

  2023cites this paper
• A Comparative Study of Oncolytic Vaccinia Viruses Harboring Different Marine Lectins in Breast Cancer Cells

  2023cites this paper
• Reporter Transgenes for Monitoring the Antitumor Efficacy of Recombinant Oncolytic Viruses

  2022cites this paper
• Emulating interactions between microorganisms and tumor microenvironment to develop cancer theranostics

  2022cites this paper
• Advances and applications of capillary electromigration methods in the analysis of therapeutic and diagnostic recombinant proteins - A Review.

  2022cites this paper
• Design Strategies and Precautions for Using Vaccinia Virus in Tumor Virotherapy

  2022influential citation
• Poxvirus Recombination

  2022cites this paper
• In Vivo Oncolytic Virotherapy in Murine Models of Hepatocellular Carcinoma: A Systematic Review

  2022cites this paper
• Direct imaging and automatic analysis in tumor-on-chip reveal cooperative antitumoral activity of immune cells and oncolytic vaccinia virus.

  2022cites this paper
• Poxvirus-driven human diseases and emerging therapeutics

  2022cites this paper
• The role of dendritic cells in neuroblastoma: Implications for immunotherapy.

  2022cites this paper
• Advances in DNA- and RNA-Based Oncolytic Viral Therapeutics and Immunotherapies

  2022cites this paper
• Inhibition of MEK-ERK pathway enhances oncolytic vaccinia virus replication in doxorubicin-resistant ovarian cancer

  2022cites this paper
• Antitumor activity of recombinant oncolytic vaccinia virus with human IL2

  2022cites this paper
• Oncolytic viruses and pancreatic cancer.

  2022cites this paper
• Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer

  2022cites this paper
• Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade

  2021cites this paper
• Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development

  2021cites this paper
• Oncolytic Vaccinia Virus Harboring Aphrocallistes vastus Lectin Inhibits the Growth of Cervical Cancer Cells Hela S3

  2021cites this paper
• Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer

  2021cites this paper
• New intratumoral immunotherapeutic approaches to inhibit the tumor growth and metastasis in breast cancer

  2021cites this paper
• Oncolytic Vaccinia Virus Expressing White-Spotted Charr Lectin Regulates Antiviral Response in Tumor Cells and Inhibits Tumor Growth In Vitro and In Vivo

  2021cites this paper
• Concurrent expression of HP-NAP enhances antitumor efficacy of oncolytic vaccinia virus but not for Semliki Forest virus

  2021cites this paper
• Activation of interferon regulatory factor 3 by replication-competent vaccinia viruses improves antitumor efficacy mediated by T cell responses

  2021cites this paper
• TREATMENT POSSIBILITIES FOR ACQUIRED AND HEREDITARY DISEASES BY GENE THERAPY: A REVIEW

  2021cites this paper
• Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer

  2021cites this paper
• Current strategies of virotherapy in clinical trials for cancer treatment

  2021cites this paper
• Pseudomonas aeruginosa ExoT induces G1 cell cycle arrest in melanoma cells

  2021cites this paper
• In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma

  2021cites this paper
• Immunotherapy of cancer

  2021cites this paper
• Oncolytic viruses as a promising therapeutic strategy for hematological malignancies.

  2021cites this paper
• Biomedical Applications of Targeted Drug Delivery, Nanotheranostic and Nuclear Medicine

  2021cites this paper
• OTT_A_230902 1011..1025

  2020cites this paper
• GLV-1h68 vaccinia virus therapy of neuroendocrine tumors

  2020cites this paper
• Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges

  2020cites this paper
• Oncolytic vaccinia virus GLV-1h68 exhibits profound antitumoral activities in cell lines originating from neuroendocrine neoplasms

  2020cites this paper
• Review on Application of Oncolytic Virotherapy of Cancer Cells in Veterinary Medicine

  2020cites this paper
• Identification of oncolytic vaccinia restriction factors in canine high-grade mammary tumor cells using single-cell transcriptomics

  2020cites this paper
• Development of oncolytic virotherapy: from genetic modification to combination therapy

  2020cites this paper
• Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model

  2020cites this paper
• Recent advances of nanomedicines for liver cancer therapy.

  2020cites this paper
• Bioinspired Artificial Tobacco Mosaic Virus with Combined Oncolytic Properties to Completely Destroy Multidrug‐Resistant Cancer

  2020cites this paper
• Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma

  2020cites this paper
• Enhancing therapeutic efficacy of oncolytic vaccinia virus armed with Beclin-1, an autophagic Gene in leukemia and myeloma.

  2020cites this paper
• The Ectopic Expression of SurvivinT34A and FilC Can Enhance the Oncolytic Effects of Vaccinia Virus in Murine Gastric Cancer

  2020cites this paper
• Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs

  2020cites this paper
• GLV-1h68 vaccinia virus therapy of neuroendocrine neoplasms

  2020cites this paper
• Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade

  2020cites this paper
• The immune microenvironment and progression of immunotherapy and combination therapeutic strategies for hepatocellular carcinoma

  2020cites this paper
• Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL‐24 gene in liver cancer cells

  2020cites this paper
• Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators

  2020cites this paper
• Engineering precision therapies: lessons and motivations from the clinic

  2020cites this paper
• The Ectopic Expression of SurvivinT34A and FilC Can Enhance the Oncolytic Effects of Vaccinia Virus in Murine Gastric Cancer OncoTargets and Therapy

  2020cites this paper
• Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer

  2020cites this paper
• Engineering oncolytic vaccinia virus to redirect macrophages to tumor cells

  2020cites this paper
• Design and Engineering of Deimmunized Vaccinia Viral Vectors

  2020cites this paper
• Target Therapy With Vaccinia Virus Harboring IL-24 For Human Breast Cancer

  2020cites this paper
• Oncolytic Sendai virus‐induced tumor‐specific immunoresponses suppress “simulated metastasis” of squamous cell carcinoma in an immunocompetent mouse model

  2019cites this paper
• Correction

  2019cites this paper
• Oncolytic virotherapy for malignant tumor: current clinical status.

  2019cites this paper
• A replication-incompetent CD154/40L recombinant vaccinia virus induces direct and macrophage-mediated antitumor effects in vitro and in vivo

  2019cites this paper
• Efficacy of a new oncolytic adenovirus armed with IL-13 against oral carcinoma models

  2019cites this paper
• OTT_A_203638 6515..6523

  2019cites this paper
• Sentinel Lymph Node–Targeted Therapy by Oncolytic Sendai Virus Suppresses Micrometastasis of Head and Neck Squamous Cell Carcinoma in an Orthotopic Nude Mouse Model

  2019cites this paper
• Evaluation of the effects of oncolytic vaccinia virus on colorectal liver metastases in cell lines and in organotypic cultures

  2019cites this paper